WHAT IS HOMEOPROPHYLAXIS?

HP has a long history, and numerous trials have taken place over the last 200 years. Studies have been recorded for Polio, Japanese encephalitis, Cholera, Chikungunya, Dengue fever, Diphtheria, Malaria, Pertussis, Small pox, and more. There have never been any deaths or injuries caused by homeoprophylaxis. You are invited to explore our complete collection of HP studies, but below are summaries of clinical studies conducted with various childhood diseases, Meningitis, as well as  Leptospirosis.

Dr Isaac Golden of Australia conducted a 15-year clinical study and ongoing trials on the use of HP for childhood diseases. His findings included a 90% effectiveness rate for preventing pertussis in those children exposed. Additionally, he found that long term health outcomes were improved for those participating in an HP program. The HP children studies had fewer allergies, colds, sore throats and asthma. (This is why our HP programs are modeled after Golden's programs.)*

In 1974 there was an epidemic of meningitis in Brazil.  Dr. Francisco Eizayaga gave 18,640 children an HP remedy, and only four cases of meningitis occurred. In the untreated group of 6,340 there were thirty-two cases contracted. This was repeated in 1988 with individuals between the ages of 0-20 years old. In the HP treated group of 65,826, only one case of meningitis was reported in the six months following. Of the 25,532 untreated individuals, seven cases were reported. Twelve months later, follow-up reported three cases in the protected group and thirteen cases in the unprotected group. This reflects eighteen times the disease attack rate in the untreated group.  Statistical analysis demonstrated homeoprophylaxis displayed 95% protection from contracting meningitis in children under six months old and 91% protection in children over 12 months old. There were no deaths, no adverse effects, and no side effects from the use of homeoprophylaxis.

Dr Gustavo Bracho, an immunologist with the Carlos J. Finlay Institute, a world-renowned center for vaccine research and production in Havana, Cuba used HP for 2.3 million people in 2007 and 2008. Dr. Bracho is Advisor to the President and General Director of Finlay Institute, and head of the Homeopathy and Biotherapic Projects at the Institute. He is an experienced researcher in molecular and cellular biology and has headed the Adjuvant Group within the Immunology Department of Finlay.

PubMed study states: "The homeoprophylactic approach was associated with a large reduction of disease incidence and control of the epidemic. The results suggest the use of HP as a feasible tool for epidemic control, further research is warranted." **(See reference.below.)

*We cannot make claims that HP treats, prevents or cures disease.